Hello everybody, I'm Sikander Alawadi from Mayo Clinic in Jacksonville, Florida. And I'm reaching you from the ASH annual meeting in 2025 from Orlando talking about a couple of interesting and I think important abstracts and presentations. So the first important thing that comes to my mind about in these abstracts and presentations that we did was about looking at real world utilization of some bispecific antibodies. The idea is that these bispecific antibodies which are very very important for our myeloma patient treatment, a lot of the data comes from clinical trials which are not always representative of how our patients are in the real world. So this particular study that we did looked at the use patterns inpatient versus outpatient side effect profile and importantly health resource utilization for patients who get bispecific antibodies in the US. This was data from Medicare claims, so very representative of the US population and while we had collected information on all bispecific antibodies, teclistomab, elranetomab and talcetomab, when we came to do the analysis, the follow up for elranetomab and talcetomab was so short that we could not have taken out much inferences out of it. So the eventual analysis happened to be with just teclistomab. What it showed was that majority of the patients, nearly 90% got their treatment in the hospital setting. They stayed in the hospital for an average of about 9 to 10 days. There was a smaller proportion of patients who started in the outpatient but when they the patients needed to be admitted or seen very frequently in the clinic to manage either the drug or any side effects etc. Were always and the patients are always concerned about the side effect called CRS or cytokine release syndrome. That was indeed the number one reason why the hospital stay was either prolonged or the patients needed to be hospitalized if they were treated in the outpatient setting. I think the bottom line, the important piece that came out of this was to understand that number one, the patterns of use in the US are very similar to what the clinical trials have suggested but these treatments do require a lot of healthcare resource and infrastructure setup to make sure that the drug can be given safely and appropriately to patients. So it is, I would say, incumbent upon the doctors, the healthcare advocacy groups, the healthcare institutions to make sure that they have the right kind of infrastructure in place so that the patients can get the treatment safely and benefit from it, stay on the treatment for the right amount of period. If our videos have helped you in any way and you are able to, please consider making a donation to help us continue this important work. Your gift will go three times as far when we reach $500,000 by the end of the year. Every contribution, big or small, makes a difference and we're deeply grateful for your support.
HealthTree • December 19, 2025